Browse SEC23B

Summary
SymbolSEC23B
NameSec23 homolog B, COPII coat complex component
Aliases CDA-II; CDAII; HEMPAS; CDAN2; Sec23 (S. cerevisiae) homolog B; congenital dyserythropoietic anemia, type II; ......
Chromosomal Location20p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasmic vesicle, COPII-coated vesicle membrane Peripheral membrane protein Cytoplasmic side Endoplasmic reticulum membrane Peripheral membrane protein Cytoplasmic side Cytoplasm, cytosol
Domain PF00626 Gelsolin repeat
PF08033 Sec23/Sec24 beta-sandwich domain
PF04815 Sec23/Sec24 helical domain
PF04811 Sec23/Sec24 trunk domain
PF04810 Sec23/Sec24 zinc finger
Function

Component of the coat protein complex II (COPII) which promotes the formation of transport vesicles from the endoplasmic reticulum (ER). The coat has two main functions, the physical deformation of the endoplasmic reticulum membrane into vesicles and the selection of cargo molecules for their transport to the Golgi complex.

> Gene Ontology
 
Biological Process GO:0006888 ER to Golgi vesicle-mediated transport
GO:0048193 Golgi vesicle transport
Molecular Function -
Cellular Component GO:0005793 endoplasmic reticulum-Golgi intermediate compartment
GO:0012507 ER to Golgi transport vesicle membrane
GO:0030117 membrane coat
GO:0030120 vesicle coat
GO:0030127 COPII vesicle coat
GO:0030133 transport vesicle
GO:0030134 ER to Golgi transport vesicle
GO:0030135 coated vesicle
GO:0030658 transport vesicle membrane
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0033116 endoplasmic reticulum-Golgi intermediate compartment membrane
GO:0048475 coated membrane
> KEGG and Reactome Pathway
 
KEGG hsa04141 Protein processing in endoplasmic reticulum
Reactome -
Summary
SymbolSEC23B
NameSec23 homolog B, COPII coat complex component
Aliases CDA-II; CDAII; HEMPAS; CDAN2; Sec23 (S. cerevisiae) homolog B; congenital dyserythropoietic anemia, type II; ......
Chromosomal Location20p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SEC23B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSEC23B
NameSec23 homolog B, COPII coat complex component
Aliases CDA-II; CDAII; HEMPAS; CDAN2; Sec23 (S. cerevisiae) homolog B; congenital dyserythropoietic anemia, type II; ......
Chromosomal Location20p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SEC23B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -1.80; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSEC23B
NameSec23 homolog B, COPII coat complex component
Aliases CDA-II; CDAII; HEMPAS; CDAN2; Sec23 (S. cerevisiae) homolog B; congenital dyserythropoietic anemia, type II; ......
Chromosomal Location20p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SEC23B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1030.651
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3210.884
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0540.973
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1880.501
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.090.961
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3120.895
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0030.993
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1790.918
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.240.9
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.180.913
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0390.987
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0870.184
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SEC23B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSEC23B
NameSec23 homolog B, COPII coat complex component
Aliases CDA-II; CDAII; HEMPAS; CDAN2; Sec23 (S. cerevisiae) homolog B; congenital dyserythropoietic anemia, type II; ......
Chromosomal Location20p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SEC23B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSEC23B
NameSec23 homolog B, COPII coat complex component
Aliases CDA-II; CDAII; HEMPAS; CDAN2; Sec23 (S. cerevisiae) homolog B; congenital dyserythropoietic anemia, type II; ......
Chromosomal Location20p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SEC23B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SEC23B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSEC23B
NameSec23 homolog B, COPII coat complex component
Aliases CDA-II; CDAII; HEMPAS; CDAN2; Sec23 (S. cerevisiae) homolog B; congenital dyserythropoietic anemia, type II; ......
Chromosomal Location20p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SEC23B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSEC23B
NameSec23 homolog B, COPII coat complex component
Aliases CDA-II; CDAII; HEMPAS; CDAN2; Sec23 (S. cerevisiae) homolog B; congenital dyserythropoietic anemia, type II; ......
Chromosomal Location20p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SEC23B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSEC23B
NameSec23 homolog B, COPII coat complex component
Aliases CDA-II; CDAII; HEMPAS; CDAN2; Sec23 (S. cerevisiae) homolog B; congenital dyserythropoietic anemia, type II; ......
Chromosomal Location20p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SEC23B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSEC23B
NameSec23 homolog B, COPII coat complex component
Aliases CDA-II; CDAII; HEMPAS; CDAN2; Sec23 (S. cerevisiae) homolog B; congenital dyserythropoietic anemia, type II; ......
Chromosomal Location20p11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SEC23B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.